Page 7 - Sysmex Inostics News Today

/PRNewswire/ -- According to the new market research report "Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC,...

/PRNewswire/ -- According to the new market research report "Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC,...

/PRNewswire/ -- Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid...

/PRNewswire/ -- The "Whole Genome And Exome Sequencing Markets" report has been added to ResearchAndMarkets.coms offering. Will all newborns receive Whole...

7 Molecular Diagnostics Recent Developments 7.1 Recent Developments - Importance and How to Use This Section 7.1.1 Importance of These Developments 7.1.2 How to Use This Section 7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx 7.3 Invitae to Acquire Genosity for $200M 7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test 7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience 7.6 Natera Revenues Grow 35 Percent 7.7 AnchorDx Closes $40M Financing Round 7...

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients News provided by Share this article Share this article BALTIMORE, April 10, 2021 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster "Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) pati...

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Biocartis Collaborating With GeneproDx, Endpoint H...

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic tr...

Global Next-Generation Sequencing (NGS) Market 27 “Global Next-Generation Sequencing (NGS) Market–Industry Trends and Forecast to 2028” New Research Report Added to Databridgemarketresearch.com database. The report width of pages: 350 Figures: 60 And Tables: 220 in it.  Global Next-Generation Sequencing (NGS) Market describes complete industry Outlook with in-depth analysis. This report also includes the complete analysis of each segment in terms of opportunity, market attractiveness i...

Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for thi...